<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473056</url>
  </required_header>
  <id_info>
    <org_study_id>AK853-U-09-002</org_study_id>
    <nct_id>NCT01473056</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety,Tolerability,Pharmacokinetics &amp; Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects</brief_title>
  <official_title>Phase I,Randomized,Double-blind,Placebo-controlled,Multiple Dose Study Evaluating Safety,Tolerability,Pharmacokinetics and Antiviral Activity of JTK-853 in HCV Genotype 1 Infected Subjects,Followed by a Genotypic Resistance Monitoring Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akros Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akros Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the safety, tolerability, pharmacokinetics and
      anti-viral activity of JTK-853 in hepatitis C virus genotype 1 infected subjects based on
      reduction in viral load (HCV RNA level) from baseline to end of treatment, followed by
      genotypic resistance monitoring for up to one year after study drug treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration (Cmax) of JTK-853 and metabolite M2</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum concentration (tmax) for JTK-853 and metabolite M2</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve during the dosing interval (AUCtau) for JTK-853 and Metabolite M2</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough concentration during multiple dosing prior to next dose (Ctrough) for JTK-853 and metabolite M2</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral load change from baseline to end of treatment</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Genotypic resistance assessment and viral load change from baseline over time</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Hepatitis C Virus Infection, Response to Therapy of</condition>
  <arm_group>
    <arm_group_label>Dose 1 JTK-853</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 JTK-853</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 JTK-853</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4 JTK-853</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JTK-853</intervention_name>
    <description>Tablets, twice a day for 3 days</description>
    <arm_group_label>Dose 1 JTK-853</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 2 JTK-853</intervention_name>
    <description>Tablets, twice a day for 3 days</description>
    <arm_group_label>Dose 2 JTK-853</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 3 JTK-853</intervention_name>
    <description>Tablets, three times a day for 3 days</description>
    <arm_group_label>Dose 3 JTK-853</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 4 JTK-853</intervention_name>
    <description>Tablets, twice a day for 3 days</description>
    <arm_group_label>Dose 4 JTK-853</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, twice a day or three times a day for 3 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females infected with chronic hepatitis C virus (HCV) infection and genotype
             1a or 1b

          2. Subjects with a viral load (HCV RNA level) of â‰¥50,000 IU/mL

          3. Subjects with a body mass index (BMI) of 18.0-36.0 kg/m2 (inclusive)

        Exclusion Criteria:

          1. Subjects should not have previously received a direct acting anti-HCV agent

          2. Subjects should not previously have received pegylated interferon/ribavirin for a
             duration of more than two weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shoji Hoshino, D.V.M</last_name>
    <role>Study Director</role>
    <affiliation>Akros Pharma Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundacion de Investigacion de Diego</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <last_update_submitted>November 17, 2011</last_update_submitted>
  <last_update_submitted_qc>November 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>JTK-853</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

